Sinsin Pharma Q1 2026: Sales +19%, Net Profit +185%

Consolidated Q1 2026: Sales 30,180M KRW (+19.2% YoY), Operating Profit 3,178M (+40.9%), Net Profit attributable to parent 2,864M (+185.0%)
EPS 189 won (vs 66 won in Q1 2025)
Separate: Sales 30,112M, Operating Profit 3,161M, Net Profit 2,846M
Debt ratio 83.98% (improved from 84.51% at FY2025), Total Assets 141,482M
R&D expense 673M (2.2% of sales), Pipeline: SS-262 (insomnia patch) Phase 1 IND approved, UIP-620 (overactive bladder patch) Phase 3 IND approved
'Sinsin Pas Arex' ranked No.1 in K-BPI anti-inflammatory category for 8 consecutive years
3 pending lawsuits (total claim 760M KRW) deemed not material by management
Received administrative sanctions in 2024 and 2025 (manufacturing suspensions) but currently selling normally